Evidence map›Paper›PMID 37153657›Full record

ArticleFrontiers in neurology2023

Clinical value of the systemic immune-inflammation index in moyamoya disease.

Erheng Liu, Chengyuan Liu, Lide Jin, Hu Zhou, Xueyi Tan, Guibo Zhang, Weihua Tao, Xiang Gao, Heng Zhao, Chao Luo and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Erheng Liu *Department of Neurosurgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Chengyuan Liu *Department of Neurosurgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Lide Jin *Department of Neurosurgery, The First People's Hospital of Yunnan Province, Kunming, China.
Hu Zhou *Department of Neurosurgery, The First People's Hospital of Yunnan Province, Kunming, China.
Xueyi TanDepartment of Neurosurgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Guibo ZhangDepartment of Neurosurgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Weihua TaoDepartment of Neurosurgery, The First People's Hospital of Yunnan Province, Kunming, China.
Xiang GaoDepartment of Neurosurgery, The First People's Hospital of Yunnan Province, Kunming, China.
Heng ZhaoDepartment of Neurosurgery, The First People's Hospital of Yunnan Province, Kunming, China.
Chao LuoDepartment of Neurosurgery, The First People's Hospital of Yunnan Province, Kunming, China.
Xuehua LiDepartment of AIDS/STDs Prevention and Control, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China.
Shuaifeng YangDepartment of Neurosurgery, The First People's Hospital of Yunnan Province, Kunming, China.
First People's Hospital of Yunnan Province · CNKunming University of Science and Technology · CNYunnan Center for Disease Control And Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Moyamoya disease (MMD) is a rare cerebrovascular disorder with unknown etiology. The underlying pathophysiological mechanism of moyamoya disease remains to be elucidated, but recent studies have increasingly highlighted that abnormal immune response may be a potential trigger for MMD. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) are inflammatory markers that can reflect the immune-inflammation state of the disease. Objective: The purpose of this study was to investigate SII, NLR, and PLR in patients with moyamoya disease. Methods: A total of 154 patients with moyamoya disease (MMD group) and 321 age- and sex-matched healthy subjects (control group) were included in this retrospective case-control study. Complete blood count parameters were assayed to calculate the SII, NLR, and PLR values. Results: The SII, NLR, and PLR values in the moyamoya disease group were significantly higher than those in the control group [754 ± 499 vs. 411 ± 205 ( Conclusion: Based on the results of this study, patients with moyamoya disease admitted for inpatient care due to acute or chronic stroke have significantly higher SII, NLR, and PLR when compared to blood samples drawn from completely healthy controls in a non-emergent outpatient setting. While the findings may suggest that inflammation plays a role in moyamoya disease, further studies are warranted to corroborate such an association. In the middle stage of moyamoya disease, there may be a more intense imbalance of immune inflammation. Further studies are needed to determine whether the SII index contributes to the diagnosis or serves as a potential marker of an inflammatory response in patients with moyamoya disease.

Indexed as

immuneinflammationmoyamoya diseaseneutrophil/lymphocyte ratioplatelet/lymphocyte ratiosystemic immune-inflammation index

Identifiers

PMID37153657
PMCPMC10157187
OpenAlexW4366590969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.